| 摘要: |
| ［摘要］ 目的 观察高病毒载量HBeAg阳性慢性乙型肝炎(CHB)患者应用替诺福韦（TDF）和恩替卡韦（ETV）治疗48周的临床疗效和安全性。方法 选取该院收治的高病毒载量HBeAg阳性慢性乙型肝炎（CHB）患者80例,随机分成两组，每组40例。TDF组应用TDF，300 mg顿服，1次/d；ETV组应用ETV 0.5 mg顿服，1次/d。观察治疗4、12、24、48周时HBV-DNA转阴率、HBeAg转阴率、ALT水平等。结果 TDF组治疗4、12、24和48周时HBV-DNA转阴率分别是62.5%、77.5%、95.0%、100%，ETV组分别是25.0%、55.0%、72.5%、95.0%,两组差异有统计学意义(P<0.05)。两组治疗4、12周时HBeAg转阴率差异无统计学意义(P>0.05)。TDF组治疗24、48周时HBeAg转阴率（65.0%、77.5%）高于ETV组（37.5%、50.0%），P<0.05。两组在ALT复常率差异无统计学意义(P>0.05)。结论 TDF治疗高病毒载量HBeAg阳性CHB疗效较ETV好,值得临床推广应用。 |
| 关键词: 替诺福韦 恩替卡韦 高病毒载量 HBeAg阳性 慢性乙型肝炎 |
| DOI：10.3969/j.issn.1674-3806.2016.10.11 |
| 分类号:R 575.1 |
| 基金项目: |
|
| Comparison of the clinical efficacy between tenofovir and entecavir in the treatment of hepatitis B E antigen-positive chronic hepatitis B with high viral load |
|
WANG He, XING Zhi-yuan, SUN Feng-bo, et al.
|
|
Department of Liver Disease, the Sixth People′s Hospital of Qingdao City, Shandong 266000, China
|
| Abstract: |
| ［Abstract］ Objective To evaluate the clinical effect and safety of tenofovir(TDF) and entecavir(ETV) on the treatment of hepatitis B E antigen-positive chronic hepatitis B(CHB) with high viral load.Methods Eighty patients with hepatitis B E antigen-positive CHB and high viral load were collected in our hospital and were randomly divided into two groups. TDF group was treated with tenofovir, 300 mg po qd; the ETV group was treated with entecavir, 0.5 mg po qd. HBV-DNA negative conversion rate, HBeAg negative conversion rate and ALT levels were observed 4,12, 24 and 48 weeks after the treatment.Results The HBV-DNA negative conversion rates in the TDF group（62.5%, 77.5%, 95.0%, 100%） were significantly higher than those in the ETV group（25.0%, 55.0%, 72.5%, 95.0%） 4 , 12, 24 and 48 weeks after the treatment(P<0.05). There were no significant differences in HBeAg negative conversion rates between the two groups 4 and 12 weeks after the treatment(P>0.05), however, HBeAg negative conversion rates of the TDF group were significantly higher than those of the ETV group 24 and 48 weeks after the treatment(P<0.05). There was no significant difference in the ALT normalization rate between the two groups(P>0.05).Conclusion TDF is more effective than ETV in the treatment of high viral load HBeAg positive CHB |
| Key words: Tenofovir(TDF) Entecavir(ETV) High viral load Hepatitis B E antigen-positive Chronic hepatitis B(CHB) |
